Drugs / ACT-280778
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01264692 | Feb 2011 → Jan 2012 | essential hypertension | Idorsia Pharmaceuticals Ltd. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ACT-280778 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01264692 ↗ |
| Known as | ACS-280778 | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068504 ↗ |
| Modality | Small molecule | — CHEMBL6068504 ↗ |
| Route | Oral | “once daily oral administration” NCT01264692 ↗ |